Pharmaceutical News

RSS

Human Genome Sciences has begun dosing patients with chronic hep C drug

Human Genome Sciences, Inc. announced today that it has begun dosing patients in a Phase 2 clinical trial of Albuferon™ (albumin-interferon alpha) in patients with chronic hepatitis C who are naïve to interferon-alpha treatments.

27 May 2004

ACE inhibitors for diabetics cut in half the risk of death

ACE inhibitors, a type of medication often used to treat high blood pressure or heart disease, can lower mortality rates for people who have diabetes -- whether they have cardiovascular disease or not, according to a study published in the June issue of Diabetes Care.

26 May 2004

Change of policy concerning generic product approvals

Following a recent judgment of the European Court of Justice in the 'Novartis' case (Case 106/01), the MHRA has decided to change its policy concerning the assessment of generic equivalents of line extension products.

26 May 2004

New company is developing advanced therapeutics for stroke victims

Arizona Engineered Therapeutics Inc., a new company based on the research of three Arizona State University professors, is moving its first drug candidate closer to clinical trials.

26 May 2004

New website helps older Texans and disabled get information that may help them obtain their prescription drugs

The Texas Department on Aging has officially launching a "Texas Cares" website -- http://www.txcares.org -- to help older Texans and people with disabilities get information that may help them obtain their prescription drugs.

25 May 2004

Zengen announces positive results of treatment for vaginal yeast infection

Zengen Inc. announced today positive phase I/II results for its proprietary molecule CZEN-002 for the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection.

25 May 2004

Anti-inflammatory medicine Roflumilast improved lung function in patients with chronic obstructive pulmonary disease

ALTANA AG’s investigational anti-inflammatory medicine roflumilast improved lung function in patients with Chronic Obstructive Pulmonary Disease (COPD) according to a placebo controlled study presented at the annual meeting of the American Thoracic Society (ATS).

25 May 2004

Collusion seen after release of flawed vaccine-autism report

America's leading scientific organization investigating the risks that mercury-containing medical products pose to our children-has posted the results of an investigative analysis of several authors relied upon for the flawed Institute of Medicine (IOM) report issued last week attempting to purport a lack of evidence to the mercury-vaccine-autism link.

25 May 2004

Launch of Zorbtive for use in the treatment of patients with short bowel syndrome

Serono, Inc., the US affiliate of Serono, announced today the launch of Zorbtive™ [somatropin (rDNA origin) for injection] for use in the treatment of patients with short bowel syndrome.

25 May 2004

Trial shows Daclizumab therapy improves multiple sclerosis outcome

A small clinical trial of patients with multiple sclerosis (MS) who did not respond to interferon alone found that adding the human antibody daclizumab improved patient outcome. Patients who received the combined therapy had a 78 percent reduction in new brain lesions and a 70 percent reduction in total lesions, along with other significant clinical improvements.

24 May 2004

Cystic Fibrosis Foundation Therapeutics awards $21 million to Vertex

Vertex Pharmaceuticals Incorporated has announced that it has expanded its drug discovery and development collaboration with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation.

24 May 2004

Medicare Drug Discount Card pricing is lower than internet and mail-order pharmacy prices

A new study by the Centers for Medicare & Medicaid Services (CMS) found that prices available from Medicare-Approved Drug Discount Cards are lower than current Internet and mail-order pharmacy prices.

24 May 2004

Innovative new cancer drug enters the first phase of clinical trials

An innovative drug with a new mechanism of action that may be effective against a range of cancers will enter the first phase of clinical trials, it was announced today (Monday) at Cancer Research UK's Senior Researchers Meeting.

24 May 2004

KETEK® (telithromycin) is highly active in vitro against Streptococcus pneumoniae (S. pneumoniae) isolates

Results from an ongoing surveillance study, PROTEKT US (Prospective Resistant Organism Tracking and Epidemiology of the Ketolide Telithromycin – United States) Year 2 (2001-2002), suggest that KETEK® (telithromycin) is highly active in vitro against Streptococcus pneumoniae (S. pneumoniae) isolates, including those resistant to other antimicrobial agents.

24 May 2004

Significant symptom relief reported in clinical trial patients with irritable bowel syndrome

Solvay Pharmaceuticals unveiled this week results from a six-month study of both male and female patients and from a subgroup analysis of males with Irritable Bowel Syndrome with Diarrhea predominance (IBS-D).

24 May 2004

Once-daily treatment with Alvesco (ciclesonide) in asthma patients has no effect on normal adrenal function

New data presented at the American Thoracic Society’s 2004 International Conference show that once-daily treatment with the investigational therapy Alvesco (ciclesonide) in mild-to-moderate asthma patients has no effect on normal adrenal function, as demonstrated by measurements of the hypothalamic-pituitary-adrenal (HPA)-axis.

24 May 2004

An antibiotic, Tigecycline produces 74 percent cure rate in cSSSI patients

An antibiotic, currently being tested in clinical trials, produced a 74 percent cure rate for hospitalized patients with possibly life-threatening, complicated skin and skin structure infections (cSSSI).

23 May 2004

Diabetes drug improves metabolic changes associated with HIV combination therapy

Use of an oral antidiabetes medication produced significant improvement in a group of patients with HIV lipodsytrophy, a syndrome involving the redistribution of fat and other metabolic changes in those receiving combination drug therapy for HIV infection.

20 May 2004

$First drug approved for hormone refractory prostate cancer that has shown a survival benefit$

First drug approved for hormone refractory prostate cancer that has shown a survival benefit

The the Food and Drug Administration (FDA) approved Taxotere (docetaxel), injection in combination with prednisone ( a steroid), for the treatment of patients with advanced metastatic prostate cancer. This is the first drug approved for hormone refractory prostate cancer that has shown a survival benefit.

19 May 2004

FDA approves new drug for bone marrow disease

The Food and Drug Administration (FDA) today announced the approval of Vidaza (azacitidine) injection, the first effective treatment for patients with Myelodysplastic Syndrome (MDS). The product was given Fast Track Status and a priority review.

19 May 2004

Pharmaceutical News

Human Genome Sciences has begun dosing patients with chronic hep C drug

ACE inhibitors for diabetics cut in half the risk of death

Change of policy concerning generic product approvals

New company is developing advanced therapeutics for stroke victims

New website helps older Texans and disabled get information that may help them obtain their prescription drugs

Zengen announces positive results of treatment for vaginal yeast infection

Anti-inflammatory medicine Roflumilast improved lung function in patients with chronic obstructive pulmonary disease

Collusion seen after release of flawed vaccine-autism report

Launch of Zorbtive for use in the treatment of patients with short bowel syndrome

Trial shows Daclizumab therapy improves multiple sclerosis outcome

Cystic Fibrosis Foundation Therapeutics awards $21 million to Vertex

Medicare Drug Discount Card pricing is lower than internet and mail-order pharmacy prices

Innovative new cancer drug enters the first phase of clinical trials

KETEK® (telithromycin) is highly active in vitro against Streptococcus pneumoniae (S. pneumoniae) isolates

Significant symptom relief reported in clinical trial patients with irritable bowel syndrome

Once-daily treatment with Alvesco (ciclesonide) in asthma patients has no effect on normal adrenal function

An antibiotic, Tigecycline produces 74 percent cure rate in cSSSI patients

Diabetes drug improves metabolic changes associated with HIV combination therapy

First drug approved for hormone refractory prostate cancer that has shown a survival benefit

FDA approves new drug for bone marrow disease

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News